Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute myeloid leukemia with CEBPA somatic mutations is a subtype of acute myeloid leukemia with recurrent genetic abnormalities, characterized by clonal proliferation of myeloid blasts harboring somatic mutations of the CEBPA gene in the bone marrow, blood and, rarely, other tissues. It can present with anemia, thrombocytopenia, and other nonspecific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement (gingivitis, splenomegaly).
Biomarker and diagnostic research for acute myeloid leukemia with CEBPA somatic mutations has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia with CEBPA somatic mutations.
116 publications have been identified in PubMed for acute myeloid leukemia with CEBPA somatic mutations. Research spans Basic Science / Preclinical (34%), Epidemiology / Natural History (22%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 39 | 34% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute myeloid leukemia with CEBPA somatic mutations
Disease patterns and progression |
25 |
22% |
Clinical study results | 17 | 15% |
Testing and diagnosis research | 11 | 9% |
Research summaries | 11 | 9% |
Patient case studies | 6 | 5% |
New treatment approaches | 6 | 5% |
Other research | 1 | 1% |
Mahmood R (2026). [PMID: 42123510](https://pubmed.ncbi.nlm.nih.gov/42123510/). *Int J Mol Sci*. [Basic Science / Preclinical]
Oya S (2026). [PMID: 41272284](https://pubmed.ncbi.nlm.nih.gov/41272284/). *Int J Hematol*. [Other]
Tripathi AK (2026). [PMID: 39937945](https://pubmed.ncbi.nlm.nih.gov/39937945/). *Unknown Journal*. [Diagnostic / Biomarker]
Tedjaseputra A (2026). [PMID: 41966916](https://pubmed.ncbi.nlm.nih.gov/41966916/). *Clin Lymphoma Myeloma Leuk*. [Review / Meta-Analysis]
de Cássia Cavaglieri R (2026). [PMID: 42031658](https://pubmed.ncbi.nlm.nih.gov/42031658/). *Clin Lymphoma Myeloma Leuk*. [Review / Meta-Analysis]
Fathima S (2026). [PMID: 41942467](https://pubmed.ncbi.nlm.nih.gov/41942467/). *Blood Cancer J*. [Clinical Trial Publication]
Qu F (2026). [PMID: 41929630](https://pubmed.ncbi.nlm.nih.gov/41929630/). *Front Cell Dev Biol*. [Epidemiology / Natural History]
Khaksari MN (2026). [PMID: 42052610](https://pubmed.ncbi.nlm.nih.gov/42052610/). *Caspian J Intern Med*. [Review / Meta-Analysis]
Prados de la Torre E (2026). [PMID: 41508698](https://pubmed.ncbi.nlm.nih.gov/41508698/). *Hematological oncology*. [Clinical Trial Publication]
Zhao L (2026). [PMID: 42085510](https://pubmed.ncbi.nlm.nih.gov/42085510/). *Oncologist*. [Diagnostic / Biomarker]